2-BOC-氨基噻唑-4-羧酸 | 83673-98-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-BOC-氨基噻唑-4-羧酸
• 中文别名: BOC-2-氨基噻唑-4-甲酸
• 英文名称: 2-((tert-butoxycarbonyl)amino)thiazole-4-carboxylic acid
• 英文别名: 2-Boc-aminothiazole-4-carboxylic acid；2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazole-4-carboxylic acid
• CAS: 83673-98-7
• 化学式: C₉H₁₂N₂O₄S
• mdl: MFCD02181057
• 分子量: 244.271
• InChiKey: PIWSRJPUYPNQJE-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252
• 密度：
  1.406±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放于惰性气体中，避免与空气接触。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-BOC-aminothiazole-4-carboxylic acid
Synonyms: 2-(tert-Butoxycarbonylamino)thiazole-4-carboxylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-BOC-aminothiazole-4-carboxylic acid
CAS number: 83673-98-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12N2O4S
Molecular weight: 244.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-BOC-氨基噻唑-4-羧酸 在 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-甲基-2-丙基[4-(氯甲酰基)-1,3-噻唑-2-基]氨基甲酸酯
  参考文献：
  名称：

  Substituted hydantoins

  摘要：

  本发明涉及一类化合物，其结构式如下： 这些化合物在治疗由MEK过度活跃引起的疾病方面具有用途。因此，这些化合物在治疗诸如癌症、认知和CNS疾病以及炎症/自身免疫疾病等疾病方面是有用的。

  公开号：

  US20060041146A1
• 作为产物：
  描述：

  2-(BOC-氨基)噻唑-4-羧酸甲酯 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以76%的产率得到2-BOC-氨基噻唑-4-羧酸
  参考文献：
  名称：

  [EN] THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
  [FR] THIAZOLOPYRIMIDINONES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR NMDA

  摘要：

  本发明涉及某些噻唑吡咯嘧啶酮化合物，用于调节NMDA受体活性，包括这些化合物的药物组合物以及治疗神经和精神疾病的方法。

  公开号：

  WO2015052226A1

文献信息

• Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
  申请人：Metabasis Therapeutics, Inc.

  公开号：US06756360B1

  公开（公告）日：2004-06-29

  Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

  提供含有FBPase抑制剂和胰岛素增敏剂的药物组合物，以及治疗糖尿病和对增加糖代谢控制、改善胰岛素敏感性、降低胰岛素水平或增强胰岛素分泌有响应的疾病的方法。
• [EN] PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH<br/>[FR] INHIBITEURS DE PROTÉINE KINASE POUR FAVORISER LA RÉGÉNÉRATION DU FOIE, OU POUR RÉDUIRE OU PRÉVENIR LA MORT DES HÉPATOCYTES
  申请人：HEPAREGENIX GMBH

  公开号：WO2018134254A1

  公开（公告）日：2018-07-26

  The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

  这项发明涉及MKK4（有丝分裂原活化蛋白激酶4）及其在促进肝再生或减少或预防肝细胞死亡中的应用。这些MKK4抑制剂选择性地抑制蛋白激酶MKK4而不是蛋白激酶JNK和MKK7。
• [EN] ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES
  申请人：DISCUVA LTD

  公开号：WO2018037223A1

  公开（公告）日：2018-03-01

  The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

  本发明涉及公式（I）的抗生素化合物，含有这些化合物的组合物，以及使用这些化合物治疗细菌性疾病和感染的方法。这些化合物在治疗革兰氏阳性和/或革兰氏阴性细菌引起的感染和疾病方面具有应用，特别是在治疗由淋病奈瑟菌引起的感染和疾病方面。
• [EN] PENICILLIN-BINDING PROTEIN INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES DE LIAISON À LA PÉNICILLINE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2018218190A1

  公开（公告）日：2018-11-29

  Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了某些含硼化合物、组合物、制剂及它们作为细菌青霉素结合蛋白的跨肽酶功能调节剂和抗菌剂的用途。在某些实施例中，本文描述的化合物抑制青霉素结合蛋白。在某些实施例中，本文描述的化合物在治疗细菌感染方面是有用的。
• Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
  申请人：Metabasis Therapeutics, Inc.

  公开号：US06489476B1

  公开（公告）日：2002-12-03

  FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.

  公式I和X的FBPase抑制剂在治疗糖尿病和其他与血糖升高或多余糖原贮存有关的疾病中很有用。